These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 26558493)
1. What next for newly diagnosed glioblastoma? Domingo-Musibay E; Galanis E Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493 [TBL] [Abstract][Full Text] [Related]
2. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484 [TBL] [Abstract][Full Text] [Related]
4. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme. Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269 [TBL] [Abstract][Full Text] [Related]
5. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470 [TBL] [Abstract][Full Text] [Related]
6. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490 [TBL] [Abstract][Full Text] [Related]
7. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?]. Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303 [TBL] [Abstract][Full Text] [Related]
8. [Our experience with targeted therapy in glioblastoma multiforme]. Kiss E; Lahm E; Vachaja J; Nagy P; Bazsó P; Fekete Z; Takácsi-Nagy Z; Pápai Z Magy Onkol; 2013 Dec; 57(4):264-8. PubMed ID: 24353992 [TBL] [Abstract][Full Text] [Related]
9. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in therapy for glioblastoma. Clarke J; Butowski N; Chang S Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224 [TBL] [Abstract][Full Text] [Related]
11. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy. Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP Front Immunol; 2024; 15():1326757. PubMed ID: 38390330 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance? Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171 [TBL] [Abstract][Full Text] [Related]
13. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. Omar AI J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354 [TBL] [Abstract][Full Text] [Related]
15. Glioblastoma Therapy in the Age of Molecular Medicine. Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755 [TBL] [Abstract][Full Text] [Related]
16. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. Wong ET; Lok E; Swanson KD Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708 [TBL] [Abstract][Full Text] [Related]
17. Patterns of care and survival of glioblastoma patients: a comparative study between 2004 and 2008 in Lyon, France. Badaoui N; Meyronet D; Cartalat-Carel S; Guyotat J; Jouanneau E; d'Hombres A; Sunyach MP; Jouvet A; Louis-Tisserand G; Archinet A; Frappaz D; Bauchet L; Honnorat J; Ducray F Rev Neurol (Paris); 2014 Mar; 170(3):222-7. PubMed ID: 24582303 [TBL] [Abstract][Full Text] [Related]
18. Management of glioblastoma: State of the art and future directions. Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924 [TBL] [Abstract][Full Text] [Related]
19. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection. Friedman GK; Spiller SE; Harrison DK; Fiveash JB; Reddy AT J Pediatr Hematol Oncol; 2013 Apr; 35(3):e123-6. PubMed ID: 23425999 [TBL] [Abstract][Full Text] [Related]